三生制药(1530.HK):授权辉瑞重磅交易落地 看好707具有BIC潜力

民生证券
22 May

SSGJ-707 授权辉瑞,首付款高达12.5 亿美元。5 月20 日,三生制药(01530.HK)宣布,公司及附属子公司沈阳三生、三生国健与辉瑞签署协议,将向辉瑞独家授予公司自主研发的突破性PD-1/VEGF 双特异性抗体SSGJ-707 在全球(不包括中国内地)的开发、生产、商业化权利。公司及沈阳三生将保留SSGJ-707 在中国内地的开发、生产、商业化权利,并基于届时商定的财务条款授予辉瑞对...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10